InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million
Retrieved on:
Wednesday, May 1, 2024
(NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023.
Key Points:
- (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023.
- Annual revenue for the year ending December 31, 2023 was NIS 356 million, and the adjusted EBITDA for the year ending December 31, 2023 was NIS 61 million, approximately 17% of revenues, as compared to an Adjusted EBITDA of NIS 51 million in our preliminary results.
- Both Q3&Q4 2023 represents the fourteenth & fifteenth consecutive quarters of profitability for InterCure5, with both Q3&Q4 2023 showing positive Adjusted EBITDA and profit from operations6.
- Alexander Rabinovitch, CEO of InterCure Noted: "Despite extraordinary external challenges this year, InterCure showed solid performance, achieving our fifteenth straight quarter of profitability.